cafepharmaGSK raises profit outlook on strong vaccine, HIV drug sales—Pfizer beats Q1 forecast despite 20% revenue drop, cuts four pipeline programs —Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal--http://bit.ly/w28kSd #earnings #gsk #pfizer #hiv #vaccines #celltherapy #astellas #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
